

## **OVERCOMING** THERAPEUTIC INERTIA

# Act Now—Therapeutic Inertia in Clinical Practice: Self-Assessment

**Problem to address:** Therapeutic inertia, also called clinical inertia, occurs when a patient has a trend of high blood glucose and therapy is not intensified in a timely manner.

Therapeutic inertia is one of the most common factors contributing to ongoing high blood glucose. Issues leading to therapeutic inertia include uncertainty about a patient's "true" blood glucose management, competing priorities during a visit, uncertainty about a patient's medication adherence, patient resistance to intensifying therapy, and simply being unaware that therapeutic inertia exists. Clinicians and quality improvement leaders often object to this term because it can be perceived as unfairly blaming clinicians for a multifactorial problem. Although we agree with this sentiment, we use the term "therapeutic inertia" in this tool because it is the term used in scientific literature.

### What you may need:

Ш	that occurred 8 to 10 weeks prior to self-assessment
	EHR analyst
	Diabetes registry
	Staff to support outreach and follow up (i.e., care coordinator, medical assistant, case manager)

#### Instructions:

Use this tool to measure how often therapeutic inertia occurs in your practice and to identify contributing factors. This tool can also be used to help detect therapeutic inertia between visits.

- **1.** Use your practice's schedule to identify approximately 24 patient encounters with a diagnosis of type 2 diabetes that occurred 8 to 10 weeks earlier. This can be done for each provider.
- **2.** Exclude new patient encounters, patients with type 1 diabetes, or pregnant patients.
- **3.** Check for recent A1C and for A1C taken during the previous visit. Also check for any other A1Cs taken within the last 12 months.
- **4.** Review the A1C in the vitals section from these patient encounters to identify eight

- records where the A1C was ≥ 8% and no diabetes medication changes were made (i.e., encounters with ongoing high blood glucose and possible therapeutic inertia).
- **5.** Use each patient's medical record to complete the Act Now –Therapeutic Inertia in Clinical Practice: Self-Assessment tool.
- **6.** Consider, as you review the cases, that therapeutic inertia is a matter of timely intensification. Timing really matters in terms of leveraging the legacy effect and supporting improved outcomes over time.

## **OVERCOMING** THERAPEUTIC INERTIA

# **Self-Assessment**

(A) Visit date from 8–10 weeks ago						
(B) Patient Identifier (DOB/MR#)						
(C) A1C at visit from row A			How long has A1C been high?			
(D) Action taken from visit in row A						
☐ Intensified current meds	☐ Referred to	o DSMES	☐ Referred for endo consult			
☐ Added new med	☐ Referred to	o pharmacist	Set follow in one month to monitor adherence and barriers	S		
<ul> <li>De-intensified therapy—lack of control due to hypoglycemia/side effects</li> </ul>	manageme	g or weight ent	☐ Prescribed professional CGM☐ Scheduled "diabetes-only" visi	t		
NOTE: If history of ASCVD or CKD, were corre	ect meds prescrib		·			
(E) Is the diabetes currently manag if action was taken at visit? (select one)	ed		YES Uknown (no follow up occured) NO, diabetes still uncontrolled due to □ Follow up issue □ Still managing blood glucose □ Other:			
(F) Reason for no action taken at vi	sit from row A	1				
☐ Clinician did not initiate med change	e □ Co-m	orbidities/acu	ite illness took priority $\ \square$ Emotional challenges			
☐ Patient refused	☐ Patier	nt opted for di	iet and exercise			
☐ Cost of meds/insurance coverage	☐ Socia	l determinants	s 🗆 Other:			
(A) Visit date from 8-10 weeks ago						
(A) Visit date from 8–10 weeks ago (B) Patient Identifier (DOB/MR#)						
(A) Visit date from 8-10 weeks ago (B) Patient Identifier (DOB/MR#) (C) A1C at visit from row A			How long has A1C been high?			
(B) Patient Identifier (DOB/MR#)			How long has A1C been high?			
(B) Patient Identifier (DOB/MR#) (C) A1C at visit from row A		o DSMES	How long has A1C been high?  □ Referred for endo consult			
(B) Patient Identifier (DOB/MR#)  (C) A1C at visit from row A  (D) Action taken from visit in row A			☐ Referred for endo consult☐ Set follow in one month to	S		
(B) Patient Identifier (DOB/MR#)  (C) A1C at visit from row A  (D) Action taken from visit in row A  Intensified current meds	☐ Referred to ☐ Referred to	o pharmacist or nutritional g or weight	<ul> <li>□ Referred for endo consult</li> <li>□ Set follow in one month to monitor adherence and barriers</li> <li>□ Prescribed professional CGM</li> </ul>			
(B) Patient Identifier (DOB/MR#)  (C) A1C at visit from row A  (D) Action taken from visit in row A  Intensified current meds  Added new med  De-intensified therapy—lack of control due to hypoglycemia/side	☐ Referred to ☐ Referred to ☐ Referred for counseling management	o pharmacist or nutritional g or weight ent	☐ Referred for endo consult☐ Set follow in one month to monitor adherence and barriers			
(B) Patient Identifier (DOB/MR#)  (C) A1C at visit from row A  (D) Action taken from visit in row A  Intensified current meds  Added new med  De-intensified therapy—lack of control due to hypoglycemia/side effects	☐ Referred to ☐ Referred to ☐ Referred for counseling managements	o pharmacist or nutritional g or weight ent	☐ Referred for endo consult ☐ Set follow in one month to monitor adherence and barriers ☐ Prescribed professional CGM ☐ Scheduled "diabetes-only" visit  YES Uknown (no follow up occured)			
(B) Patient Identifier (DOB/MR#)  (C) A1C at visit from row A  (D) Action taken from visit in row A  Intensified current meds  Added new med  De-intensified therapy—lack of control due to hypoglycemia/side effects  NOTE: If history of ASCVD or CKD, were correctly managerif action was taken at visit?	☐ Referred to ☐ Referred to ☐ Referred for counseling management meds prescrib	o pharmacist or nutritional g or weight ent oed	Referred for endo consult  Set follow in one month to monitor adherence and barriers  Prescribed professional CGM Scheduled "diabetes-only" visi  YES Uknown (no follow up occured) NO, diabetes still uncontrolled due to Follow up issue Still managing blood glucose			
(B) Patient Identifier (DOB/MR#)  (C) A1C at visit from row A  (D) Action taken from visit in row A  Intensified current meds  Added new med  De-intensified therapy—lack of control due to hypoglycemia/side effects  NOTE: If history of ASCVD or CKD, were corrected in the control of the contr	☐ Referred to ☐ Referred to ☐ Referred for counseling management meds prescrib	o pharmacist or nutritional g or weight ent oed	Referred for endo consult  Set follow in one month to monitor adherence and barriers  Prescribed professional CGM Scheduled "diabetes-only" visi  YES Uknown (no follow up occured) NO, diabetes still uncontrolled due to Follow up issue Still managing blood glucose	t		
(B) Patient Identifier (DOB/MR#)  (C) A1C at visit from row A  (D) Action taken from visit in row A  Intensified current meds  Added new med  De-intensified therapy—lack of control due to hypoglycemia/side effects  NOTE: If history of ASCVD or CKD, were corrected in the control of the contr	□ Referred to □ Referred to □ Referred for counseling management meds prescribe    Ped   Co-m	o pharmacist or nutritional g or weight ent  ped	Referred for endo consult  Set follow in one month to monitor adherence and barriers  Prescribed professional CGM Scheduled "diabetes-only" visit  YES Uknown (no follow up occured) NO, diabetes still uncontrolled due to Follow up issue Still managing blood glucose Other:	t		

Learn more at professional.diabetes.org/TherapeuticInertia